# **SECURITIES AND EXCHANGE COMMISSION**

SECURITES AND	EXCIMINGE	
Wa	ashington, D.C. 20549	
	FORM 8-K	
C	URRENT REPORT	
Pursuai	nt to Section 13 or 15(d) of	
the Secur	rities Exchange Act of 1934	
Date of Report (Dat	e of earliest event reported) April 2	19, 2004
INCARA PHARMACEUTICALS CORPORATION  (Exact name of registrant as specified in its charter)		
	Delaware	
(State or other jurisdiction of incorporation)		
0-50481 (Commission File Number)		56-1953785 (IRS Employer ID Number)

P.O. Box 14287

# Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 8-K

79 T. W. Alexander Drive 4401 Research Commons, Suite 200 Research Triangle Park, North Carolina (Address of principal executive offices)

27709 (Zip Code)

Registrant s telephone number, including area code (919) 558-8688

### Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 8-K

Item 5. Other Events and Regulation FD Disclosure

On April 19, 2004, Incara Pharmaceuticals Corporation issued a press release announcing the private placement of 41,040,000 shares of its common stock, resulting in gross proceeds of approximately \$10.26 million. A copy of this press release is attached as an exhibit.

Item 7. Financial Statements and Exhibits

(c) Exhibits

Exhibit 99.1 Press release dated April 19, 2004

# Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 8-K

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

INCARA PHARMACEUTICALS CORPORATION

Date: April 19, 2004

/s/ Richard W. Reichow

Richard W. Reichow Executive Vice President and Chief Financial Officer